IVIg in the treatment of patients with factor VIII inhibitors

  • Y. Sultan
  • U. Nydegger
  • M D Kazatchkine
  • F. Rossi
  • M. Algiman
  • G. Dietrich
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 386)


Ten years ago M. Kazatchkine, U. Nydegger, and Y. Sultan decided to treat patients with acquired hemophilia using intravenous immunoglobulins (IVIg). This was during a meeting in Denmark about autoimmune diseases and IVIg. In 1983, several authors had reported on the efficacy of IVIg in autoimmune diseases such as idiopathic thrombocytopenic purpura in children1,2 and adults,3 immune neutropenia,2,4 and red cell aplasia.5 Autoantibodies to factor VIII (F.VIII) occurring in either otherwise healthy patients or during the course of a more characterized immune disorder such as disseminated lupus erythematosus (DUE) and rheumatoid polyarthritis seemed to be good models. One major reason is that the neutralizing capacity of autoantibodies to F.VIII is easily and reproducibly quantified using the Bethesda assay, while this is not the case in most of the autoimmune diseases mentioned above.


Factor Viii Idiopathic Thrombocytopenic Purpura Inhibitor Titer Factor Viii Inhibitor High Dose Intravenous Immunoglobulin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    P. Imbach, S. Barandun, V. d’Apuzzo et al.. High dose intravenous gammaglobulin, for idiopathic thrombocytopenic purpura in childhood. Lancet i: 1228 (1981).Google Scholar
  2. 2.
    J.B. Bussel, R.P. Kimberly, R.D. Inman et al.. Intravenous gammaglobulin treatment of chronic idiopathic thrombocytopenic purpura. Blood 62: 480 (1983).PubMedGoogle Scholar
  3. 3.
    R.E. Schmidt, U. Budde, G. Schafer et al. High dose intravenous immunoglobulin for idiopathic thrombocytopenic purpura. Lancet ii: 475 (1981).Google Scholar
  4. 4.
    S. Pollack, C. Cunningham-Rundles, E.M. Smithwick, S. Barandun, R.A. Good, High dose intravenous gammaglobulin for autoimmune neutropenia, N Engl J Med 307: 243 (1982).CrossRefGoogle Scholar
  5. 5.
    JP. Clauvel, W. Vainchenker, A. Herrera et al.. Treatment of pure red cell aplasia by high dose intravenous immunoglobulins, Br J Haematol 55: 380 (1983).PubMedCrossRefGoogle Scholar
  6. 6.
    Y. Sultan, M.D. Kazatchkine, P. Maisonneuve, U.E. Nydegger, Anti-idiotypic suppression of autoantibodies to factor VIII (anti-haemophilic factor) by high-dose intravenous gammaglobulin. Lancet ii: 765 (1984).Google Scholar
  7. 7.
    F. Rossi, Y. Sultan, M.D. Kazatchkine, Anti-idiotypes against autoantibodies and alloantibodies to factor VIIIC (anti-hemophilic factor) are present in therapeutic polyspecific normal immunoglobulins, Clin Exp Immunol 74: 311 (1988).PubMedGoogle Scholar
  8. 8.
    G. Borradori, A. Hirt, A. Luthy, H.P. Wagner, P. Imbach, Haemophilia due to factor VIII inhibitors in a patient suffering from an autoimmune disease. Treatment with intravenous immunoglobulin, Blut 48: 403 (1984).CrossRefGoogle Scholar
  9. 9.
    R. Zimmerman, B. Kommereil, J. Herenberg, W. Eich, K. Rother, KL. SchimpfGoogle Scholar
  10. 10.
    Intravenous IgG for patients with spontaneous inhibitor to factor VIII, Lancet i:273 (1985).Google Scholar
  11. 11.
    D. Green, H.C. Kwaan, An acquired factor VIII inhibitor responsive to high dose gammaglobulin, Thromb Haemost 58: 1005 (1987).PubMedGoogle Scholar
  12. 11.
    L.O. Carreras, G.N. Perez, D.L. Xavier, A.N. Blanco, L.B. Penalva, Autoimmune factor VIII inhibitor responsive to gammaglobulin without in vitroneutralization, Thromb Haemost 60: 343 (1988).PubMedGoogle Scholar
  13. 13.
    Y. Sultan, F. Rossi, M.D. Kazatchkine, Recovery from anti-VIIIC (anti-hemophilic factor) autoimmune disease is dependent on generation of anti-idiotypes against anti-FVIHc autoantibodies, Proc Natl Acad Sci USA 84: 828 (1987).PubMedCrossRefGoogle Scholar
  14. 14.
    C. Tiarks, L. Pechet, RE. Humphreys, Development of anti-idiotypic antibodies in a patient with a factor VIII autoantibody. Am J Hematol 32: 217 (1989).PubMedCrossRefGoogle Scholar
  15. 15.
    M. Algiman, G. Dietrich, U.E. Nydegger, D. Boyeldieu, Y. Sultan, M.D. Kazatchkine, Antibodies to factor VIII (anti-hemophilic factor) in healthy individuals, Proc Natl Acad Sci USA 89: 3795 (1992).PubMedCrossRefGoogle Scholar
  16. 16.
    G. Dietrich, M. Algiman, Y. Sultan, U.E. Nydegger, M.D. Kazatchkine, Origin of anti-idiotypic activity against anti-factor VIII autoantibodies in pools of normal human immunoglobulin G (IVIg), Blood 79, 11: 2946 (1992).PubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1995

Authors and Affiliations

  • Y. Sultan
    • 1
  • U. Nydegger
    • 2
  • M D Kazatchkine
    • 3
  • F. Rossi
    • 3
  • M. Algiman
    • 1
  • G. Dietrich
    • 3
  1. 1.Centre des Hémophiles Hôpital CochinParisFrance
  2. 2.Division of TransfusionInselspitalBernSwitzerland
  3. 3.Hôpital BroussaisFrance

Personalised recommendations